Medivir’s board of directors has resolved to repurchase own shares

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announce that Medivir’s board of directors has resolved to use the authorisation given by the annual general meeting regarding repurchases of Medivir class B shares.

The repurchases will be carried out in batches over time, not longer than up to the next annual general meeting. The execution of the repurchases will depend on market conditions and the repurchases are to be made in accordance with applicable rules. Among other things, the number of shares repurchased on any given day, with the exception for any block transactions, cannot amount to more than 25 percent of the average daily volume during the four calendar weeks immediately preceding the week during which shares are repurchased. Repurchases may only be made at a price per share within the price range applicable, i.e. the range between the highest purchase price and the lowest selling price. In line with the purposes set out in the authorisation given by the annual general meeting, the repurchases are made to flexibly and suitably distribute capital to the shareholders and promote a more appropriate capital structure in light of the current financial position of Medivir. Repurchases may be made of a maximum number of shares corresponding to one tenth of the total number of shares in the company, i.e. a maximum of 2,696,603 shares. As of today, Medivir holds no own shares (treasury shares).

For further information, please contact:
Ola Burmark, CFO Medivir AB, mobile: +46 (0)725-480 580.

Medivir is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 08.30 CET on 6 May 2015.

About Medivir
Medivir is a research based pharmaceutical company with a research focus on infectious diseases and oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical need. Our commercial organization provides a growing portfolio of specialty care pharmaceuticals on the Nordic market. Medivir is listed on the Nasdaq Stockholm Mid Cap List.


About Us

Medivir develops innovative pharmaceuticals for the treatment of cancer. The company specializes within protease inhibitor research and nucleotide/nucleoside science.The research is conducted in all phases of pharmaceutical development, from idea to clinical phase III studies. The development work is conducted both in-house and through partnerships.Medivir is listed on the Nasdaq Stockholm Mid Cap List.


Documents & Links